Intramedullary apoptosis of hematopoietic cells in myelodysplastic syndrome patients can be massive: apoptotic cells recovered from high-density fraction of bone marrow aspirates
Open Access
- 15 August 2000
- journal article
- Published by American Society of Hematology in Blood
- Vol. 96 (4) , 1388-1392
- https://doi.org/10.1182/blood.v96.4.1388
Abstract
A higher percentage of apoptotic cells (apoptotic index or AI) is consistently found in bone marrow (BM) biopsies compared to BM aspirates of patients with myelodysplastic syndrome (MDS). Most studies have only investigated the low-density fraction (LDF) mononuclear cells from BM aspirates following density separation for AI determination. In the present study, both LDF and high-density fraction (HDF) cells for AI were examined by electron microscopy (EM) in 10 MDS patients and 4 healthy donors. Matched BM biopsies were subjected to AI detection by in situ end labeling (ISEL) of fragmented DNA. The results indicate that in LDF and HDF cells, AI is consistently higher in MDS patients (8.5% vs 1.5%, respectively; P = .039) compared to healthy donors (27% vs 4%, respectively; P = .004). The BM biopsy AI was also higher in MDS patients than in healthy donors (3+ vs 0+, respectively; P = .036). In addition, in MDS patients, more apoptotic cells were found in HDF cells than in LDF cells (27% vs 8.5%, respectively;P = .0001). All stages of maturation, ranging from blasts to terminally mature cells belonging to all 3 lineages, were represented in the dying cells in both compartments. Using EM, typical Pelger-Huett–type cells appeared to be apoptotic granulocytes. Both LDF and HDF cells should be examined for an accurate estimation of apoptotic cells because AI would be underestimated if only the LDF cells were studied. Ultrastructural studies consistently show a higher AI in BM biopsies compared to BM aspirates despite the correction factor of HDF cells provided by AI. This may represent the actual extant state, which could conceivably be due to a higher concentration of proapoptotic signals in the biopsies.Keywords
This publication has 13 references indexed in Scilit:
- Extensive apoptosis of bone marrow cells as evaluated by the in situ end-labelling (ISEL) technique may be the basis for ineffective haematopoiesis in patients with myelodysplastic syndromes.European Journal of Haematology, 2009
- Fas/Apo-1(CD95) expression and apoptosis in patients with myelodysplastic syndromesLeukemia, 1997
- Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietinLeukemia Research, 1997
- Excessive Proliferation Matched by Excessive Apoptosis in Myelodysplastic Syndromes: The Cause-Effect RelationshipLeukemia & Lymphoma, 1997
- Is apoptosis a massive process in myelodysplastic syndromes?British Journal of Haematology, 1996
- Apoptosis in bone marrow of myelodysplastic syndrome patients [letter; comment]Blood, 1996
- Simultaneous assessment of cell kinetics and programmed cell death in bone marrow biopsies of myelodysplastics reveals extensive apoptosis as the probable basis for ineffective hematopoiesisAmerican Journal of Hematology, 1995
- Novel in situ double labeling for simultaneous detection of proliferation and apoptosis.Journal of Histochemistry & Cytochemistry, 1994
- Apoptosis is a Common Histopathological Finding in Myelodysplasia: the Correlate of Ineffective HaematopoiesisLeukemia & Lymphoma, 1990
- Characterization of blast cells in chronic granulocytic leukaemia in transformation, acute myelofibrosis and undifferentiated leukaemiaBritish Journal of Haematology, 1985